Home/SolasCure/Oliver Schofield

OS

Oliver Schofield

Chief Financial Officer

Therapeutic Areas

Wound Care Dermatology

SolasCure Pipeline

Drug	Indication	Phase
Aurase Wound Gel	Chronic Wounds (e.g., Venous Leg Ulcers, Diabetic Foot Ulcers)	Phase 2

Leadership Team at SolasCure

Chief Executive Officer

Andy Weymann, MD

Chief Development Officer

Dr. Bela Kelety

Chief Technology Officer

Antoinette van Dijk, MD

Director Clinical and Medical Affairs

View full SolasCure profile